Korea’s medical tourism sector is projected to reach 2.01 million foreign patients in 2025, the first time annual arrivals have passed two million since national tracking began in 2009. Maeil Business Newspaper reported that the 2025 total would mark the third consecutive year of record foreign patient volumes. Recovery has been steep. Foreign patient numbers fell to 120,000 in 2020, climbed back to 610,000 in 2023, reached 1.17 million in 2024, and are forecast at 2.01 million in 2025. Since 2009, more than 7.06 million foreign patients have travelled to Korea for medical treatment.
The curve tells a familiar story about medical tourism demand. Volume collapses when borders close. It then returns faster than domestic planners expect, because the drivers behind it do not go away. Patients travel for care that is better, cheaper, faster, or unavailable at home, and Korea has spent two decades building supply against all four. The 2.01 million projection is less a rebound than proof that Korea has rebuilt its foreign patient pipeline and pushed it past the pre-pandemic ceiling.
Korea medical tourism economic impact
The Korea Institute of Industrial Economics and Trade calculated that foreign patients and their companions spent KRW 12.5 trillion in Korea last year. Medical treatment accounted for KRW 3.3 trillion of that total, and the rest flowed into hotels, shopping, dining, wellness, and local tourism. Domestic production inducement from medical tourism is estimated at KRW 22.8 trillion. Foreign patients stay an average of 7.2 days and spend an average of KRW 7.75 million each.
Those figures explain why Korea treats medical tourism as economic policy and not as a hospital revenue line. A patient who pays for treatment, then for hotels, retail, dining, and wellness across a week, generates trickle-down demand that a domestic patient does not. The bulk of it sits outside the clinic. The KRW 7.75 million average spend is the number that matters for positioning, because it ranks the market by yield rather than headcount and steers policy toward higher-spending foreign patients.
Korea Tourism Organization marketing
The Korea Tourism Organization, or KTO, has driven much of this growth through targeted international marketing. Maeil Business Newspaper reported that the KTO ran 17 overseas marketing sessions across 10 countries last year, each tuned to local treatment demand, and that these produced 12,882 consultations and KRW 19 billion in sales. For 2025 the KTO plans to expand to 20 sessions across 12 countries, adding the United States, Thailand, Uzbekistan, and Saudi Arabia as new target markets and reaching into second-tier cities beyond the main capitals.
Lee Dong-seok, who leads the medical wellness team at the KTO, described medical tourism as “a high-value-added tourism sector” built on public-private cooperation. He said the organisation intends to diversify by country, region, and medical field, and to expand convergence products that combine medical care, wellness, shopping, and local tourism.
The convergence language places Korea deliberately in the hybrid middle of the health tourism spectrum. A cardiology or oncology admission sits at the clinical, high-involvement end of that spectrum; skin care, K-beauty, and wellness add-ons sit toward the self-guided wellness end. Bundling the two is a yield strategy, because it lifts the per-patient spend figure and widens the market beyond patients with a strict clinical need. The mix is the point.
Source markets and concentration risk
China led foreign patient numbers last year with 619,000 visitors, followed by Japan with 600,000, and the two markets together supplied more than 60 per cent of the total. Taiwan grew sharply to 186,000 visitors, a 122.5 per cent rise on the year before, and the United States reached 173,000, its highest level since 2009. In Southeast Asia, Thailand recorded 58,000 medical tourists and Singapore 43,000, while Indonesia rose 104.6 per cent and Malaysia 106.8 per cent year on year.
Two markets supplying more than 60 per cent of arrivals is concentration risk. It is the structural weakness behind the expansion plan. A destination economy that leans this heavily on China and Japan is exposed to a bilateral dispute, a currency swing, or a visa change in either market. That push into the United States, Saudi Arabia, and Uzbekistan reads as a deliberate hedge against the concentration, and the sharp growth in Taiwan and Southeast Asia suggests the diversification is already taking hold.
Regional dispersal is happening inside Korea as well. Maeil Business Newspaper reported that non-metropolitan areas grew strongly last year, with Busan up 151.5 per cent, Jeju up 114.7 per cent, and Daegu up 31.4 per cent, spreading medical tourism beyond Seoul. The report also cited a high-value package for Mongolian government officials priced at KRW 2 million per person, pairing medical check-ups and skin care with sightseeing in Gyeongju, yachting in Haeundae, and K-beauty shopping in Daegu, an illustration of the convergence product the KTO is scaling.
What to watch
These projections are real, but they remain projections, and three tests will show whether the 2.01 million figure holds. Conversion is the first, whether marketing sessions in Saudi Arabia, Uzbekistan, and the United States turn into confirmed foreign patient volumes rather than consultations. Yield is the second, and it matters more, because Korea’s economic case rests on the KRW 7.75 million average spend and not on headcount alone; watch which specialities draw the highest-spending patients from the Middle East and the United States. Durability is the third, whether growth in Busan, Jeju, and Daegu can decentralise medical tourism into a national capability rather than a Seoul concentration with regional spillover.
